Human leukemic cell lines express a truncated intracellular 160 kDa ERBB2 receptor
(English)Manuscript (preprint) (Other academic)
It has recently been demonstrated that ERBB specific tyrosine kinase inhibitors display antineoplastic activity in human leukemic cell devoid of functional ERBB receptors. The present study was undertaken in order to identify any putative target for these drugs. Flow cytometry experiments demonstrate the presence of an immunoreactive ERBB2 protein of intracellular localization and Western blot analysis visualized an ERBB2 protein of approximately 160 kDa. Exposing leukemia cells to tunicamycin did not alter the size of the truncated ERBB2 protein. The ERBB2 gene was alternative spliced with an absence of exon 5 containing the start codon for the full-length protein. In conclusion we demonstrate a nonglycosylated 160 kDa ERBB2-receptor protein with an alternative in-frame start codon in human leukemia cell lines.
Leukemia, ERBB2-receptor, variant, glycosylation, exon
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:liu:diva-75548OAI: oai:DiVA.org:liu-75548DiVA: diva2:508125